<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>


Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  

Company Overview - May 2017
May 10, 2017
5:00pm - 6:00pm EDT

Trovagene's senior management team will host a conference call on Wednesday, MAy 10th, 2017, at 5:00 pm EDT (2:00 pm PDT) to discuss results and update investors on the Company's progress.

May 2, 2017
4:00pm - 4:30pm EDT

Trovagene's Chief Executive Officer, Bill Welch, will be presenting at the Pioneers 2017 Joseph Gunnar Conference on Tuesday, May 2nd, at 4:00 pm EDT at the Mandarin Hotel in New York City.

April 4, 2017
9:00am - 9:30am EDT

Trovagene will present at the MicroCap Conference on Tuesday, April 4th, 2017 at 9:00 am EDT at the Essex House in NY

email print
Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593

E-mail    ir@trovagene.com